用于阿尔茨海默病的双重功能和前期药物应用的多西尔和梅曼丁衍生物
Karna Terpstra1, Citlali Gutiérrez1, Kai Gui1
1Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Matthews Avenue, Urbana, Illinois 61801, United States.
针对粉样质斑块的新型双重功能化合物对阿尔茨海默病的治疗具有前景. 这些药物能更有效地向大脑输送多内佩西尔和美曼,
科学领域:
- 神经科学
- 药理学
- 药物发现
背景情况:
- 目前使用乙胆酶 (AChE) 和N- 甲基- d- 酸盐受体 (NMDAR) 抑制剂治疗阿尔茨海默病的疗效和副作用有限.
- 开发新的治疗策略对于控制阿尔茨海默病的进展至关重要.
研究的目的:
- 通过对现有的阿尔茨海默氏症药物 (多尼佩西尔和美曼丁) 结合化β (Aβ) 向片段来制造双重功能化合物.
- 通过改善对大脑中的粉样质斑块的向传递来提高药物的疗效和减少副作用.
主要方法:
- 合成含有Aβ向片段的双重功能化合物.
- 在体外测定和分子对接以评估化合物对Aβ纤维素和酶抑制的亲和力.
- 在5xFAD小鼠体内研究以评估大脑吸收和前药特征.
主要成果:
- 成功合成的化合物对小鼠大脑中的Aβ纤维和染色的粉状斑块表现出亲和力.
- 通过分子对接证实,donepezil基化合物在结合后表现出改变的ACHE抑制.
- 孟坦因衍生化合物显示出良好的脑吸收,但缺乏直接的NMDAR抑制,在体内作为释放孟坦因的前药物.
结论:
- 双功能的化合物为阿尔茨海默病的向药物提供了潜在的策略.
- 这些化合物可以在粉样蛋白丰富的大脑区域中代谢释放活性药物,这表明治疗潜力有所改善.
- 这些类似前药物的进一步开发可能会导致更有效的阿尔茨海默病治疗方法.
更多相关视频
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
相关概念视频
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
